来自 SSO 内分泌和头颈部疾病网站工作组的关于嗜铬细胞瘤和副神经节瘤的更新，第 2 部分，共 2 部分：嗜铬细胞瘤和副神经节瘤的围手术期管理和结果。
Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma.
机构信息
Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Surgery, The Ohio State University, Columbus, OH, USA.
出版信息
Ann Surg Oncol. 2020 May;27(5):1338-1347. doi: 10.1245/s10434-020-08221-2. Epub 2020 Feb 28.
Abstract
This is the second part of a two-part review on pheochromocytoma and paragangliomas (PPGLs). In this part, perioperative management, including preoperative preparation, intraoperative, and postoperative interventions are reviewed. Current data on outcomes following resection are presented, including outcomes after cortical-sparing adrenalectomy for bilateral adrenal disease. In addition, pathological features of malignancy, surveillance considerations, and the management of advanced disease are also discussed.
摘要
这是关于嗜铬细胞瘤和副神经节瘤（PPGLs）的两部分综述的第二部分。在这一部分中，回顾了围手术期管理，包括术前准备、术中及术后干预。介绍了目前关于切除术后结果的数据，包括双侧肾上腺疾病行保留皮质肾上腺切除术的结果。此外，还讨论了恶性肿瘤的病理特征、监测注意事项以及晚期疾病的治疗。
相似文献
1
Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma.来自 SSO 内分泌和头颈部疾病网站工作组的关于嗜铬细胞瘤和副神经节瘤的更新，第 2 部分，共 2 部分：嗜铬细胞瘤和副神经节瘤的围手术期管理和结果。
Ann Surg Oncol. 2020 May;27(5):1338-1347. doi: 10.1245/s10434-020-08221-2. Epub 2020 Feb 28.
2
Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.患有冯·希佩尔-林道病、2型多发性内分泌腺瘤病或1型神经纤维瘤病的患者，其综合征性副神经节瘤和嗜铬细胞瘤切除术后的围手术期结局。
Surgery. 2017 Dec;162(6):1259-1269. doi: 10.1016/j.surg.2017.08.002. Epub 2017 Sep 14.
3
Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma.来自 SSO 内分泌/头颈部疾病工作组的嗜铬细胞瘤和副神经节瘤更新。第 1 部分，共 2 部分：嗜铬细胞瘤和副神经节瘤发病机制和诊断的进展。
Ann Surg Oncol. 2020 May;27(5):1329-1337. doi: 10.1245/s10434-020-08220-3. Epub 2020 Feb 28.
4
Preoperative Management of Pheochromocytoma and Paraganglioma.《嗜铬细胞瘤和副神经节瘤的术前管理》。
Front Endocrinol (Lausanne). 2020 Sep 29;11:586795. doi: 10.3389/fendo.2020.586795. eCollection 2020.
5
Surgical management of hereditary pheochromocytoma.遗传性嗜铬细胞瘤的外科治疗
J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5. doi: 10.1016/j.jamcollsurg.2003.12.001.
6
Laparoscopic resection of periadrenal paraganglioma in a patient with multiple endocrine neoplasia type 2A.2A 型多发性内分泌腺瘤病患者肾上腺旁嗜铬细胞瘤的腹腔镜切除术
Surg Laparosc Endosc Percutan Tech. 2011 Feb;21(1):e31-3. doi: 10.1097/SLE.0b013e3182074c72.
7
Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas.嗜铬细胞瘤的腹腔镜手术：肾上腺切除术、部分切除术、副神经节瘤切除术。
J Urol. 1998 Aug;160(2):330-4. doi: 10.1016/s0022-5347(01)62886-6.
8
Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.嗜铬细胞瘤和副神经节瘤的降压治疗：当前的管理和治疗特点。
Endocrine. 2014 Apr;45(3):469-78. doi: 10.1007/s12020-013-0007-y. Epub 2013 Jul 2.
9
MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma.内分泌疾病管理：遗传性嗜铬细胞瘤保留肾上腺手术的结果。
Eur J Endocrinol. 2016 Jan;174(1):R9-18. doi: 10.1530/EJE-15-0549. Epub 2015 Aug 21.
10
Pheochromocytoma/Paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma.嗜铬细胞瘤/副神经节瘤：围手术期血压管理综述及与嗜铬细胞瘤相关基因突变的最新进展。
J Clin Hypertens (Greenwich). 2013 Jun;15(6):428-34. doi: 10.1111/jch.12084. Epub 2013 Mar 15.
引用本文的文献
1
Pheochromocytomas and Paragangliomas-Current Management.嗜铬细胞瘤和副神经节瘤——当前的治疗方法
Cancers (Basel). 2025 Mar 19;17(6):1029. doi: 10.3390/cancers17061029.
2
Carotid stenosis complicating a vagus paraganglioma: A dually rare case.颈动脉狭窄并发迷走神经副神经节瘤：一例双重罕见病例。
Int J Surg Case Rep. 2025 Jan;126:110751. doi: 10.1016/j.ijscr.2024.110751. Epub 2024 Dec 17.
3
Circulatory characteristics of early mobilization after surgery for bilateral pheochromocytoma: a case report.术后双侧嗜铬细胞瘤早期活动的循环特征：病例报告。
J Med Case Rep. 2024 Oct 31;18(1):529. doi: 10.1186/s13256-024-04833-4.
4
Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma.嗜铬细胞瘤和副神经节瘤患者手术方法及治疗结果的进展
Best Pract Res Clin Endocrinol Metab. 2025 Jan;39(1):101954. doi: 10.1016/j.beem.2024.101954. Epub 2024 Sep 21.
5
Paraganglioma of the Neck: A Rare Case With Spinal Metastasis.颈部副神经节瘤：一例罕见的伴有脊柱转移的病例。
Case Rep Oncol Med. 2024 Apr 26;2024:2025115. doi: 10.1155/2024/2025115. eCollection 2024.
6
Effects of Peptide Receptor Radiotherapy in Patients with Advanced Paraganglioma and Pheochromocytoma: A Nation-Wide Cohort Study.肽受体放射性核素治疗对晚期副神经节瘤和嗜铬细胞瘤患者的影响：一项全国性队列研究
Cancers (Basel). 2024 Mar 29;16(7):1349. doi: 10.3390/cancers16071349.
7
Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma.EMP1、2、3 在肾上腺皮质肿瘤和嗜铬细胞瘤中的表达。
Int J Mol Sci. 2023 Aug 21;24(16):13016. doi: 10.3390/ijms241613016.
8
Pheochromocytoma: Clinical Experience From a Single Tertiary Care Center in India.嗜铬细胞瘤：来自印度一家三级医疗中心的临床经验。
Cureus. 2023 Jul 10;15(7):e41671. doi: 10.7759/cureus.41671. eCollection 2023 Jul.
9
Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.组蛋白去乙酰化酶抑制剂作为一种治疗嗜铬细胞瘤和副神经节瘤的新方法。
Oncol Res. 2023 Feb 3;30(5):211-219. doi: 10.32604/or.2022.026913. eCollection 2022.
10
Abandonment of intravenous volume expansion after preoperative receipt of α-blockers in patients with adrenal pheochromocytoma was not an independent risk factor for intraoperative hemodynamic instability.在接受肾上腺嗜铬细胞瘤术前α受体阻滞剂治疗的患者中，放弃静脉容量扩张并不是术中血流动力学不稳定的独立危险因素。
Front Endocrinol (Lausanne). 2023 Apr 21;14:1131564. doi: 10.3389/fendo.2023.1131564. eCollection 2023.
本文引用的文献
1
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.α-受体阻滞剂在嗜铬细胞瘤切除术中对血流动力学控制的疗效：一项随机对照试验。
J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-91. doi: 10.1210/clinem/dgz188.
2
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.NCCN 指南解读：神经内分泌和肾上腺肿瘤，第 2.2018 版。
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.
3
Minimally Invasive Surgery (MIS) in Children and Adolescents with Pheochromocytomas and Retroperitoneal Paragangliomas: Experiences in 42 Patients.儿童和青少年嗜铬细胞瘤及腹膜后副神经节瘤的微创手术：42例患者的经验
World J Surg. 2018 Apr;42(4):1024-1030. doi: 10.1007/s00268-018-4488-y.
4
A cost-conscious approach to robotic adrenalectomy.一种具有成本意识的机器人肾上腺切除术方法。
J Robot Surg. 2018 Dec;12(4):607-611. doi: 10.1007/s11701-018-0782-9. Epub 2018 Jan 31.
5
Fifteen years of adrenalectomies: impact of specialty training and operative volume.十五年肾上腺切除术：专科培训与手术量的影响
Surgery. 2018 Jan;163(1):150-156. doi: 10.1016/j.surg.2017.05.024. Epub 2017 Nov 8.
6
Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery.嗜铬细胞瘤和副神经节瘤的术前基因检测会影响手术方式及肾上腺手术范围。
Surgery. 2018 Jan;163(1):191-196. doi: 10.1016/j.surg.2017.05.025. Epub 2017 Nov 7.
7
Each procedure matters: threshold for surgeon volume to minimize complications and decrease cost associated with adrenalectomy.每一个步骤都很重要：外科医生手术量的阈值，以尽量减少并发症并降低与肾上腺切除术相关的成本。
Surgery. 2018 Jan;163(1):157-164. doi: 10.1016/j.surg.2017.04.028. Epub 2017 Nov 6.
8
Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.临床预测指标在嗜铬细胞瘤和副神经节瘤患者中的作用。
Ann Surg Oncol. 2017 Nov;24(12):3624-3630. doi: 10.1245/s10434-017-6074-1. Epub 2017 Sep 7.
9
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.恶性嗜铬细胞瘤和副神经节瘤：272例55岁以上患者
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305. doi: 10.1210/jc.2017-00992.
10
ENDOCRINOLOGY IN PREGNANCY: Pheochromocytoma in pregnancy: case series and review of literature.妊娠内分泌学：妊娠期间嗜铬细胞瘤：病例系列和文献复习。
Eur J Endocrinol. 2017 Aug;177(2):R49-R58. doi: 10.1530/EJE-16-0920. Epub 2017 Apr 5.
Zotero 插件